Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 33Breast Diseases 3Neoplasms by Site 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Intraductal, Noninfiltrating 2Breast Neoplasms, Male 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1Low Grade Serous Ovarian Cancer 1Locoregional Recurrence 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2 Negative Breast Cancer 1Endometrial Neoplasms 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Breast Neoplasm Female 1Breast Carcinoma In Situ 1Anatomic Stage III Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Advanced Breast Carcinoma 1

Interventions

abemaciclib 3Fulvestrant 3Anastrozole 3ribociclib 2palbociclib 2exemestane 2Tamoxifen 2Letrozole 2trastuzumab deruxtecan 1taxane 1pertuzumab 1elacestrant 1dalpiciclib 1Trastuzumab 1STX-478 1RAD1901 1Metformin 1Leflunomide 1Imlunestrant 1Gonadotropin-Releasing Hormone 1Genotype 1Body Height 1Blood Pressure 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Diseases × Anastrozole × 90 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07581834 2026-05-12

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Fujian Cancer Hospital

Phase 2 Recruiting
2,000 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT04964934 2026-04-21

SERENA-6

AstraZeneca

Phase 3 Active not recruiting
315 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡